🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

RecruitingNAAges 18 Years - 75 YearsAllGeneral Hospital of Shenyang Military Region
NCT07388420 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The severity of hypertriglyceridemia induced acute pancreatitis (HTG-AP) is closely related to the serum triglyceride (TG) levels. The higher the TG levels, the greater the risk of developing severe acute pancreatitis (SAP). Previous expert consensus has pointed out that the key to treating HTG-AP is to rapidly lower serum TG levels to below 5.65 mmol/L. Evolocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, which is often used to treat familial hypercholesterolemia, mixed dyslipidemia and atherosclerotic cardiovascular disease. At the same time, evolocumab also has the effect of reducing TG and may provide a feasible option for the management of HTG-AP. However, its efficacy and safety in reducing TG in patients with HTG-AP remain controversial. This study is a multicenter randomized controlled trial to evaluate the efficacy and safety of adding evolocumab to c

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18\~75 years * Patients with HTG-AP * Mixed hyperlipidemia * Sign the informed consent form Exclusion Criteria: * Patients who have received lipid-lowering drugs or blood purification treatment within one week before enrollment * Patients who have used evolocumab within one month before enrollment * Patients who are accompanied by diseases that can seriously affect the survival * Patients who have participated in the clinical research of other drugs within one month * Patients who are pregnant or breastfeeding * Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies * Other circumstances that researchers consider not suitable for participation in this study
💊

What it tests

  • Evolocumab 140 MG/ML [Repatha]
  • Conventional lipid-lowering therapy
📍

Where

1 site
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
Shenyang, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy